Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma board meetings
132 filed, newest first. Page 3 of 3.
Nov 2012
2 Nov · Board meeting
Board of Directors inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2012.
Aug 2012
13 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 10, 2012 has proposed the allotment of 22,98,748 warrants convertible into 22,98,748 equity shares of Rs.10 each of the Company on preferential basis to the promoters and to strategic investors. This proposal is subject to the approval of the share holders at the ensuing Annual General Meeting of the Company.1 Aug · Board meeting
Inter alia will transact the following business : (1) Take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2012; (2)Take on record and approve the Audited financial results of the company for the financial year ended March 31, 2012; (3) Propose issue and allotment of warrants on preferential basis to the promoters and to strategic investors, subject to the approval of the members; (4) Approve the audited accounts of the Company for the F.Y ended March 31, 2012 along with the notice for AGM, Directors Report and Corporate Governance Report; (5) Decide on the book closure date and AGM date.
May 2012
11 May · Board meeting
Board of Directors of the Company at its meeting held on May 10, 2012 has noted appointment of Mr. M P George as Chief Operating Officer of the Company and has appointed Mr. Promod Kumar, as independent Director of the Company in place of Mr. Arun Bhan, ex-Independent Director of the company who has resigned from the Board due to his nominations in United Nations agencies in Ireland.
Apr 2012
30 Apr · Board meeting
To consider, and take on record, interalia, the Unaudited Financial Results (UFR) for the 4th quarter ended on, March 31, 2012.
Feb 2012
4 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 03, 2012, has accepted resignation rendered by Mr. Arun Bhan, Independent Director of the Company due to his nominations in United Nations agencies in Ireland and the Company is in the process of appointing a suitable one place of him.
Jan 2012
23 Jan · Board meeting
To consider, and take on record, the Unaudited Financial Results (UFR) for the third quarter, ended on, December 31, 2011.
Oct 2011
24 Oct · Board meeting
To consider, and take on record, the Unaudited Financial Results (UFR) for the 2nd Quarter ended on September 30, 2011.
Jul 2011
27 Jul · Board meeting
To consider and take on record, the Audited Financial Results of the Company for the entire financial year ended March 31, 2011, Unaudited Financial Results (UFR) for the first quarter ended June 30, 2011 and to discuss the AGM related matters.
Apr 2011
28 Apr · Board meeting
To consider, and take on record, the Audited Financial Results of the Company (Instead of 4th quarter unaudited Financial Results) for the entire financial year ended on March 31, 2011.
Jan 2011
14 Jan · Board meeting
To consider, and take on record, the Unaudited Financial Results for the third quarter, ended on, December 31, 2010.
Oct 2010
25 Oct · Board meeting
Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the 2nd quarter, ended on, September 30, 2010.
Jul 2010
20 Jul · Board meeting
Among other things, the main purpose of the meeting is to consider, and take on record, the Unaudited Financial Results for the first quarter, ended on, June 30, 2010 and Audited Financial Results for the year ended on March 31, 2010.
Apr 2010
29 Apr · Board meeting
Meeting on 14 May 2010: “Unaudited Financial Results for the qtr ended March 31, 2010”
Dec 2009
21 Dec · Board meeting
To consider and take on record, the Unaudited Financial Results for the third quarter, ended on December 31, 2009.
Oct 2009
15 Oct · Board meeting
Meeting on 31 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
20 Jul · Board meeting
To consider, and take on record, the unaudited financial results for the first quarter, ended on June 30, 2009, and to discuss the AGM related matters.
Jun 2009
18 Jun · Board meeting
Among other things, to take on record the Audited Financial Results for the year ended on March 31, 2009 and appropriation of profit & recommendation of Dividend if any, for the financial year, 2008-09.
May 2009
14 May · Board meeting
Among other things, to take on record the sales performance of the Company, up to March 31, 2009.
Jan 2009
7 Jan · Board meeting
Meeting on 30 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
16 Oct · Board meeting
To consider, and take on record, the unaudited financial results for the second quarter, ended on September 30, 2008.
Jul 2008
23 Jul · Board meeting
To consider, and take on record, the unaudited financial results for the first quarter, ended on June 30, 2008 and to discuss the AGM related matters.
Jun 2008
13 Jun · Board meeting
Among other things, to take on record the Audited Financial Results for the year ended on March 31, 2008 and appropriation of profit and declaration of Dividend, for the financial year, 2007-08.
Apr 2008
24 Apr · Board meeting
Board of Directors in their Meeting held on April 18, 2008, took on record the matter that, M/s Basav Chem. Limited, Sangli, Maharashtra, became 100% subsidiary of M/s Bal Pharma Limited, w.e.f. December 06, 2007, and all formalities in this regard had been completed."15 Apr · Board meeting
Company had informed the Exchange regarding a Board Meeting scheduled to be held on April 16, 2008, among other things, to take on record the sales performance of the Company, up to March 31, 2008. The Company has now informed the Exchange that the meeting of the Board of Directors of the Company which was scheduled to be held on April 16, 2008, has been postponed, due to unavoidable circumstances, and the said meeting is rescheduled to be held on April 18, 2008, to transact the business as detailed in the earlier notice.7 Apr · Board meeting
Among other things, to take on record the sales performance of the Company, up to March 31, 2008.
Jan 2008
11 Jan · Board meeting
Among other things, to take on record the unaudited financial results for the 3rd quarter, ended on December 31, 2007.
Oct 2007
10 Oct · Board meeting
Among other things, to take on record the unaudited financial results for the quarter ended September 30, 2007.
Jul 2007
24 Jul · Board meeting
To consider: a) Unaudited financial results for the first quarter ending June 30, 2007. b) To discuss the AGM related matters.
Jun 2007
26 Jun · Board meeting
Among other things, to take on record the audited financial results for the year ended March 31, 2007.
May 2007
31 May · Board meeting
To consideration the routine matters only.
Jan 2007
18 Jan · Board meeting
Among other things, to take on record the unaudited financial results for the quarter ended 31st December, 2006.